ELI LILLY & Co
LLYAPI behind this page
LLY Q3 2025 request
Playground key active
/api/financials?ticker=LLY&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 17,600.8 | 11,439.1 | +53.9% |
Show Product Lines breakouts |
|||
| Cardiometabolic Health | 13,177.9 | 7,407 | +77.9% |
| Cardiometabolic Health · Non Us | 4,310.7 | 1,890 | +128.1% |
| Cardiometabolic Health · US | 8,867.2 | 5,517 | +60.7% |
| Collaboration and Other Revenue [Member] | 1,270.3 | 867.5 | +46.4% |
| Immunology | 1,362.4 | 1,185.7 | +14.9% |
| Immunology · Non Us | 589 | 491.6 | +19.8% |
| Immunology · US | 773.4 | 694.1 | +11.4% |
| Jardiance | 959 | 686.4 | +39.7% |
| Jardiance · Milestone Payments, Sales-based | 200 | — | — |
| Jardiance · Non Us | 534.8 | 350.5 | +52.6% |
| Jardiance · US | 424.2 | 335.9 | +26.3% |
| Mounjaro | 6,515.1 | 3,112.7 | +109.3% |
| Mounjaro · Non Us | 2,965 | 728 | +307.3% |
| Mounjaro · US | 3,550.1 | 2,384.7 | +48.9% |
| Neuroscience | 315.7 | 351.8 | -10.3% |
| Neuroscience · Non Us | 76.1 | 150.5 | -49.4% |
| Neuroscience · US | 239.6 | 201.3 | +19.0% |
| Oncology | 2,407.6 | 2,231.8 | +7.9% |
| Oncology · Non Us | 1,032.6 | 937.5 | +10.1% |
| Oncology · US | 1,375 | 1,294.3 | +6.2% |
| Other | 337.2 | 262.8 | +28.3% |
| Other cardiometabolic health | 1,063.9 | 1,048.7 | +1.4% |
| Other cardiometabolic health · Non Us | 446.1 | 445.5 | +0.1% |
| Other cardiometabolic health · US | 617.7 | 603.3 | +2.4% |
| Other immunology | 460.9 | 306.1 | +50.6% |
| Other immunology · Non Us | 270.9 | 212.3 | +27.6% |
| Other immunology · US | 190 | 93.8 | +102.6% |
| Other oncology | 937.4 | 862.5 | +8.7% |
| Other oncology · Non Us | 442.8 | 447.1 | -1.0% |
| Other oncology · US | 494.7 | 415.5 | +19.1% |
| Other · Non Us | 292.4 | 155.8 | +87.7% |
| Other · US | 44.8 | 107 | -58.1% |
| Product | 16,330.5 | 10,571.6 | +54.5% |
| Taltz | 901.5 | 879.6 | +2.5% |
| Taltz · Non Us | 318.1 | 279.3 | +13.9% |
| Taltz · US | 583.4 | 600.3 | -2.8% |
| Trulicity | 1,051.8 | 1,301.4 | -19.2% |
| Trulicity · Non Us | 345 | 366 | -5.7% |
| Trulicity · US | 706.9 | 935.3 | -24.4% |
| Verzenio | 1,470.2 | 1,369.3 | +7.4% |
| Verzenio · Non Us | 589.8 | 490.4 | +20.3% |
| Verzenio · US | 880.3 | 878.8 | +0.2% |
| Zepbound | 3,588.1 | 1,257.8 | +185.3% |
| Zepbound · Non Us | 19.8 | — | — |
| Zepbound · US | 3,568.3 | 1,257.8 | +183.7% |
Show Business Segments breakouts |
|||
| Reportable Segment | 17,600.8 | 11,439.1 | +53.9% |
Show Geography breakouts |
|||
| CN | 560.4 | 459.9 | +21.9% |
| Europe | 3,498.1 | 1,628.3 | +114.8% |
| JP | 554.7 | 429.1 | +29.3% |
| Non Us | 6,300.8 | 3,625.5 | +73.8% |
| Rest of world | 1,687.7 | 1,108.2 | +52.3% |
| US | 11,300 | 7,813.6 | +44.6% |
| Cost of Revenue | 3,008.3 | 2,170.8 | +38.6% |
Show Business Segments breakouts |
|||
| Reportable Segment | 3,008.3 | 2,170.8 | +38.6% |
| Research And Development Expense Excluding Acquired In Process Cost | 3,465.7 | 2,734.1 | +26.8% |
Show Product Lines breakouts |
|||
| Early-stage · Reportable Segment | 1,249.6 | 995.3 | +25.6% |
| Late-stage · Reportable Segment | 2,216.1 | 1,738.8 | +27.4% |
| Selling, General & Administrative | 2,740.7 | 2,099.8 | +30.5% |
Show Business Segments breakouts |
|||
| Reportable Segment | 2,740.7 | 2,099.8 | +30.5% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 655.7 | 2,826.4 | -76.8% |
Show Business Segments breakouts |
|||
| Reportable Segment | 655.7 | 2,826.4 | -76.8% |
| Restructuring Settlement And Impairment Provisions | 364.9 | 81.6 | +347.2% |
| Non-Operating Income (Expense) | 133.1 | -62 | +314.7% |
| Cost Of Sales Operating Expenses And Other Net | 10,368.4 | 9,850.7 | +5.3% |
| Income Before Taxes | 7,232.4 | 1,588.4 | +355.3% |
| Income Tax Expense (Benefit) | 1,649.9 | 618.1 | +166.9% |
Show Business Segments breakouts |
|||
| Reportable Segment | 1,649.9 | 618.1 | +166.9% |
| Net Income | 5,582.5 | 970.3 | +475.3% |
Show Business Segments breakouts |
|||
| Reportable Segment | 5,582.5 | 970.3 | +475.3% |
| EPS (Basic) | 6.22 | 1.08 | +475.9% |
| EPS (Diluted) | 6.21 | 1.07 | +480.4% |
| Wtd Avg Shares (Basic) | 896.9 | 901 | -0.5% |
| Wtd Avg Shares (Diluted) | 898.8 | 905 | -0.7% |
| Interest Expense | 179.6 | 192.7 | -6.8% |
Show Business Segments breakouts |
|||
| Reportable Segment | 179.6 | 192.7 | -6.8% |
| Interest Income | 65 | 47.8 | +36.0% |
Show Business Segments breakouts |
|||
| Reportable Segment | 65 | 47.8 | +36.0% |
| Other Non-Operating Income (Expense) | 179.4 | 20.9 | +758.4% |
| Net Income (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 3 | 11.8 | -74.6% |
| Retained Earnings | 5,582.5 | 970.3 | +475.3% |
| Comprehensive Income | 6,092.2 | 1,074 | +467.2% |
| Other Comprehensive Income | 509.7 | 103.7 | +391.5% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 509.7 | 103.7 | +391.5% |
| Income Loss From Equity Method Investments (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 45.4 | 26 | +74.6% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 9,791.9 | 3,369 | +190.6% |
| Short-Term Investments | 121.6 | 149.4 | -18.6% |
| Accounts Receivable | 16,107.4 | 10,294.8 | +56.5% |
| Other Receivables Net Current | 3,349.8 | 1,756.9 | +90.7% |
| Inventory | 12,180.4 | 7,459.8 | +63.3% |
| Prepaid Expense Current | 20,248.7 | 8,250.6 | +145.4% |
| Other Assets Current | 271.5 | 134.6 | +101.7% |
| Total Current Assets | 62,071.3 | 31,415.1 | +97.6% |
| Non-Current Assets | |||
| Long Term Investments | 2,808.3 | 3,200.2 | -12.2% |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure | 2,808.3 | 3,200.2 | -12.2% |
| Goodwill | 5,898 | — | — |
| Deferred Tax Assets | 8,962.7 | 7,392.3 | +21.2% |
| Property, Plant & Equipment | 22,316 | 16,171.8 | +38.0% |
| Other Non-Current Assets | 6,432.4 | 5,121.8 | +25.6% |
| Total Assets | 114,935.4 | — | — |
Show Business Segments breakouts |
|||
| Reportable Segment | 114,935.4 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 6,446.7 | 6,537.3 | -1.4% |
| Current Liabilities | |||
| Debt Current | 1,633 | 2,074.3 | -21.3% |
| Accounts Payable | 4,262.2 | 2,886.5 | +47.7% |
| Employee Related Liabilities Current | 1,965.7 | 1,703.3 | +15.4% |
| Sales Rebates And Discounts | 17,620.2 | 12,429.7 | +41.8% |
| Taxes Payable Current | 9,444.4 | — | — |
| Other Liabilities Current | 5,215.4 | 5,580.3 | -6.5% |
| Total Current Liabilities | 40,140.9 | 24,674.1 | +62.7% |
| Non-Current Liabilities | |||
| Long-Term Debt | 40,873.6 | 29,045.4 | +40.7% |
| Accrued Income Taxes Noncurrent | 6,293.6 | 3,878.8 | +62.3% |
| Other Non-Current Liabilities | 3,776.5 | 2,239.4 | +68.6% |
| Liabilities Noncurrent | 50,943.7 | 36,612.1 | +39.1% |
| Long-Term Debt (Q) | — | — | — |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level2 · Estimate Of Fair Value Fair Value Disclosure | 39,991.3 | 28,023.3 | +42.7% |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure | 42,506.6 | 29,824.4 | +42.5% |
| Estimate Of Fair Value Fair Value Disclosure | 39,991.3 | 28,023.3 | +42.7% |
Show Long-Term Debt Type breakouts |
|||
| Foreign Currency Denominated Debt | 6.79 | 6.5 | +4.5% |
| Other Liabilities | |||
| Minority Interest | 57.5 | 80.7 | -28.7% |
| Stockholders' Equity | |||
| Common Stock | 591.4 | 593.9 | -0.4% |
| Additional Paid In Capital Common Stock | 7,231.9 | 7,339.6 | -1.5% |
| Retained Earnings | 22,252 | 13,627.2 | +63.3% |
| Common Stock Shares Held In Employee Trust | -3,013.2 | -3,013.2 | 0.0% |
| Accumulated Other Comprehensive Income | -3,206.3 | -4,274.8 | +25.0% |
| Treasury Stock Common Value | -62.5 | -32.7 | -91.1% |
| Total Stockholders' Equity | 23,793.3 | 14,240 | +67.1% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 23,850.8 | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -2,173 | -2,638.8 | +17.7% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 264.6 | 264.4 | +0.1% |
| Accumulated Net Unrealized Investment Gain Loss | -6.1 | -16.7 | +63.5% |
| Accumulated Other Comprehensive Income | -3,206.3 | -4,274.8 | +25.0% |
| Accumulated Translation Adjustment | -1,291.8 | -1,883.7 | +31.4% |
| Additional Paid In Capital | 7,231.9 | 7,339.6 | -1.5% |
| Common Stock | 591.4 | 593.9 | -0.4% |
| Noncontrolling Interest | 57.5 | 80.7 | -28.7% |
| Retained Earnings | 22,252 | 13,627.2 | +63.3% |
| Treasury Stock Common | -62.5 | -32.7 | -91.1% |
| Trust For Benefit Of Employees | -3,013.2 | -3,013.2 | 0.0% |
| Total Liabilities & Equity | 114,935.4 | 75,606.9 | +52.0% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 1,411.3 | 1,281.8 | +10.1% |
Show Business Segments breakouts |
|||
| Reportable Segment | 1,411.3 | 1,281.8 | +10.1% |
| Increase Decrease In Deferred Income Taxes | -958.9 | -1,716.4 | +44.1% |
| Stock-Based Compensation | 489.9 | 503.7 | -2.7% |
| Increase Decrease In Other Operating Capital Net | -4,418.9 | -3,160.1 | -39.8% |
| Other Operating Activities Cash Flow Statement | 681.5 | 163.7 | +316.3% |
| Net Cash from Operations | 13,588.4 | 6,344.1 | +114.2% |
| Investing Activities | |||
| Payments To Acquire Other Property Plant And Equipment | -5,294.3 | -3,561.8 | -48.6% |
| Proceeds From Sale And Maturity Of Other Investments | 832 | 318 | +161.6% |
| Payments To Acquire Other Investments | -518 | -525.1 | +1.4% |
| Other Payments To Acquire Businesses | -549.4 | -947.7 | +42.0% |
| Payments To Acquire In Process Research And Development | -2,584.3 | -3,094.6 | +16.5% |
| Other Investing Activities | -55.8 | 430.2 | -113.0% |
| Net Cash from Investing | -8,169.8 | -7,381 | -10.7% |
| Financing Activities | |||
| Payments Of Dividends | -4,038.5 | -3,512.1 | -15.0% |
| Proceeds From Repayments Of Short Term Debt | -4,337.6 | -4,894.1 | +11.4% |
| Proceeds From Issuance Of Long Term Debt | 13,167.2 | 11,417.1 | +15.3% |
| Repayments Of Long Term Debt | -778.1 | -664.2 | -17.1% |
| Share Repurchases | -2,600.3 | -446.1 | -482.9% |
| Proceeds From Payments For Other Financing Activities | -746.9 | -445.1 | -67.8% |
| Net Cash from Financing | 665.8 | 1,455.5 | -54.3% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 439.1 | 131.8 | +233.2% |
| Net Change in Cash | 6,523.5 | 550.4 | +1085.2% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 9,791.9 | 3,369 | +190.6% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.